A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

Gastric Cancer Clinical Trial

Official title:

A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05238883
• Other study ID #: HFB-200301-01
• Secondary ID: 2021-006231-25
• Status: Recruiting
• Phase: Phase 1
• Start date: March 10, 2022
• Est. completion date: December 2026

Study information

• Verified date: April 2024
• Source: HiFiBiO Therapeutics
• Contact: Emily Lefkovitz, Clinical Trial Manager
• Phone: +1(513)579-9911
• Email: e.lefkovitz[@]Medpace.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses of HFB200301 as a monotherapy or in combination with tislelizumab until a safe and tolerable dose of HFB200301 as a single agent or combination therapy is determined. During the expansion part, participants will take the dose of HFB200301 as a monotherapy or in combination with tislelizumab that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have.

Description:

This is a Phase 1a/1b, first in human, open-label, dose escalation and expansion study in adults with advanced cancers. The study will comprise of 1. A Screening Period 2. A Treatment Period during which participants will receive the study drug on the first day of each cycle 3. A Follow-up Period

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 170
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Previously received the following lines of systemic therapy for the

advanced/metastatic disease:

• Gastric cancer: at least 2 lines of therapy
• Renal cell carcinoma: at least 2 lines of therapy
• Melanoma:
• BRAF V600E mutant: must have received at least 2 lines of therapy
• BRAF V600E wild type: must have received at least 1 line of therapy
• Sarcoma: at least 1 line of therapy
• Testicular germ cell tumor: at least 2 lines of therapy
• Cervical cancer: at least 2 lines of therapy
• Mesothelioma: at least 2 lines of therapy
• Non-small cell lung cancer: at least 2 lines of therapy
• Head and neck squamous cell carcinoma: at least 2 lines of therapy
• Suitable site to biopsy at pre-treatment and on-treatment
• Measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 or modified RECIST (mRECIST) for mesothelioma
• Eastern Cooperative Oncology Group performance status of 0 or 1

Exclusion Criteria:

• Systemic anti-cancer therapy within 2 weeks prior to start of study drug or within 4 weeks for immune-oncologic therapy
• For soft tissue sarcoma and testicular germ cell tumor patients only: prior immune therapy
• Therapeutic radiation therapy within the past 2 weeks
• Prior exposure to agents targeting the Tumor Necrosis Factor Receptor type 2 (TNFR2) receptor
• Active autoimmune disease requiring systemic treatment in the previous 2 years
• Systemic steroid therapy (>10 mg/day of prednisone or equivalent) or any immune suppressive therapy = 14 days before first dose
• Persisting toxicity of =Grade 2 (=Grade 1 for diarrhea) relating to prior anti cancer

therapy with the following exceptions:

• All grades of alopecia are acceptable
• Endocrine dysfunction on replacement therapy is acceptable
• Severe or unstable medical condition, including uncontrolled diabetes, coagulopathy, or unstable psychiatric condition
• Major surgery within 4 weeks of the first dose of study drug
• History or presence of drug or non-drug induced interstitial lung disease or pneumonitis =Grade 2. For combination only: non-small cell lung cancer patients, mesothelioma or patients with significantly impaired pulmonary function or who require supplemental oxygen at baseline must undergo an assessment of pulmonary function at screening
• History of allergic reactions, immune related reactions, or cytokine release syndrome (CRS) attributed to compounds of similar chemical or biologic composition to monoclonal antibodies or any excipient of HFB200301
• Using sensitive substrates of major cytochrome P450 (CYP450) enzymes
• Known active malignancy, with the exception of the specific cancer under investigation in this trial, that required treatment within the previous 2 years
• For combination only:
• Prior randomization in a tislelizumab study regardless of the treatment arm, until the primary and key secondary endpoints of the study have read out
• Hypersensitivity to tislelizumab or any of its excipients.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Renal Cell
• Cervical Cancer
• Gastric Cancer
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Mesothelioma
• Neoplasms, Germ Cell and Embryonal
• Non Small Cell Lung Cancer
• Renal Cell Carcinoma
• Sarcoma
• Squamous Cell Carcinoma of Head and Neck
• Testicular Germ Cell Tumor

Intervention

Drug:
• HFB200301
Participants will be administered HFB200301 as described in the experimental arm.
• Tislelizumab
Participants will be administered tislelizumab as described in the experimental arm.

Locations

Country	Name	City	State
Spain	Hospital Universitario Vall d'Hebron	Barcelona
Spain	Hospital Universitario 12 de Octubre	Madrid
Spain	Hospital Clinico Universitario de Valencia	Valencia
United States	NEXT Virginia Cancer Specialists	Fairfax	Virginia
United States	The University of Texas, MD Anderson Cancer Center	Houston	Texas
United States	Mayo Clinic	Jacksonville	Florida
United States	USC/Norris Comprehensive Cancer Center	Los Angeles	California
United States	Mayo Clinic	Rochester	Minnesota
United States	Washington University School of Medicine	Saint Louis	Missouri
United States	Mayo Clinic	Scottsdale	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
HiFiBiO Therapeutics

Countries where clinical trial is conducted

United States,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events (AEs), serious AEs (SAEs), dose-limiting toxicities (DLTs), and tolerability (dose interruptions, reductions, and dose intensity)		assessed up to 3 years
Primary	To determine a Recommended Phase 2 Dose (RP2D) during Dose Expansion		assessed up to 3 years
Secondary	Objective Response Rate (ORR)		assessed up to 3 years
Secondary	Disease Control Rate (DCR)		assessed up to 3 years
Secondary	Duration of Response (DOR)		assessed up to 3 years
Secondary	Progression Free Survival (PFS)		assessed up to 3 years
Secondary	Maximum serum concentration (Cmax)		average of 3 years
Secondary	Terminal half-life (T1/2)		average of 3 years
Secondary	Area under the concentration versus time curve (AUC)		average of 3 years
Secondary	Serum concentration for measurement of anti-HFB200301 antibodies		average of 3 years
Secondary	To assess the pharmacodynamic (PD) effects of HFB200301 as a single agent and in combination	Percent change in immunologic changes to immune cells	average of 3 years